Nebenwirkungen · Mektovi
Mektovi 15 mg film-coated tablets Mektovi 45 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13
HOS-140023 · Präparat HOS-098436
Ocular events In the Combo 450 ISP, RPED was reported in 22.3% (83/372) of patients. RPED was Grade 1 (asymptomatic) in 15.6% (58/372) of patients, Grade 2 in 5.1% (19/372) of patients and Grade 3 in 1.6 % (6/372) of patients. Most events were reported as retinopathy, retinal detachment, subretinal fluid, macular oedema, and central serous chorioretinopathy and led to dose interruptions or dose modifications in 3.8% (14/372) of patients. The median time to onset of the first event of RPED (all grades) was 1.4 month (range 0.0 to 17.5 months). Visual impairment, including vision blurred and reduced visual acuity, occurred in 23.1% (86/372) of patients. Visual impairment was generally reversible.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T17:08:00Z · SHA-256 08ad2922c2ddc9f92addbbd839b466e9afc2c43b31a5f2435e8602f8f26327da · Passage b68b10ecad9b8b9894cc719446d54680862b5453be03201d2f0501812760590f · Zeichen 9040–9743 im Abschnitt